The continuous use of triazoles can result in the development of drug resistance. Azole-resistant clinical isolates, spontaneous and induced mutants of Aspergillus fumigatus have been documented. The azoles block the ergosterol biosynthesis pathway by inhibiting the enzyme 14-a-demethylase, product of the CYP51. Fungal azole resistance involves both amino acid changes in the target site that alter drug-target interactions and those that decrease net azole accumulation. The reduced intracellular accumulation has also been correlated with overexpression of multidrug resistance (MDR) efflux transporter genes of the ATP-binding cassette (ABC) and the major facilitator superfamily (MFS) classes. About 20 genes are involved in the A. fumigatus ergosterol biosynthesis pathway. There are several duplicated genes in this pathway. Interestingly, erg3 and erg11 showed two copies in A. fumigatus. In general, Aspergillus spp. have proportionally more MFS transporter encoding genes than Saccharomyces cerevisiae, S. pombe, and Neurospora crassa. The drug H ' (12 and 14 spanners) sub-families are also proportionally greater than in the other species. Although the numbers of ABC transporter encoding genes are comparable, again the Aspergillus spp. have more ABC transporters related to multidrug permease than the other fungal species.
Introduction
Aspergillus fumigatus is the most common species of Aspergillus and causes life-threatening pulmonary disease in severely immunocompromised patients [1] . The treatment of these patients has been largely limited to therapy with the polyene drug amphotericin B, the broad-spectrum triazoles such as itraconazole or voriconazole, and/or with the echinocandin caspofungin [2] . Amphotericin B therapy can be highly toxic and can result in nephrotoxicity, whereas triazoles are fungistatic and can be limited by drug resistance [3] . This reviews aims to summarize the present state of knowledge about azole resistance, the ergosterol biosynthesis pathway and the transporter-encoding genes in A. fumigatus.
In spite of its safety profile and good therapeutic performance, the continuous use of triazoles can result in the development of drug resistance and a number of itraconazole-resistant clinical isolates [3] , spontaneous and induced mutants of A. fumigatus have been documented [4 Á/6] . Manavathu et al . [7] reported the isolation of A. fumigatus mutants resistant to amphotericin B following UV irradiation. All amphotericin B-resistant isolates showed a significant level of crossresistance to nystatin but not azoles. Manavathu et al. [5] selected two spontaneous itraconazole-resistant mutants that had minimum inhibitory concentrations (MICs) of 16 and 8 mg/ml for itraconazole. Both mutants showed concomitant increases in MICs for ketoconazole and miconazole, but not for amphotericin B. The accumulation of [ 3 H]itraconazole in these mutants was reduced to approximately 80% and 60%, respectively, compared to the susceptible parent. Although the respiratory inhibitor carbonyl cyanide m-chlorophenyl hydrazone reduced the intracellular accumulation of itraconazole, this happened to the same extent in both wild type and mutant strains. These results suggest that the reduced accumulation of itraconazole in these mutants is due to diminished permeability of the drug and perhaps not due to active energy dependent efflux. In contrast, sterol composition of four clinical isolates of A. fumigatus resistant to itraconazole was determined by gaschromatography-mass spectrometry and compared with that of four susceptible strains [8] . For all strains, the major sterol was ergosterol. Sterol compositions were qualitatively and quantitatively similar for the resistant and susceptible strains. These results suggest that itraconazole resistance is not related, for the strains studied, to alterations in the ergosterol synthesis pathway.
Mosquera and Denning [9] tested 17 clinical isolates of A. fumigatus, for most of which MICs of itraconazole were elevated against posaconazole, ravuconazole, and voriconazole. Posaconazole was the most active agaisnt itraconazole-susceptible isolates. However, the authors observed a complex pattern of cross-resistance and hypersusceptibility with voriconazole and ravuconazole, suggesting marked differences in activity and mechanisms of resistance. Manavathu et al. [10] selected voriconazole-resistant mutants of A. fumigatus from drug-susceptible clinical isolates and examined their in vitro susceptibility to amphotericin B and other azoles. They observed low-level cross resistance between voriconazole and other drugs and that the observed reduced in vitro susceptibility to voriconazole may not be due to reduced accumulation of the drug in the mycelia.
Dannaoui et al . [4] recovered four A. fumigatus isolates at different times from a patient treated with itraconazole for a pulmonary Aspergillus infection. Random amplified polymophic DNA (RAPD) patterns obtained with each of them were identical, suggesting that the same strain was recovered over time and had acquired resistance to itraconazole. In another study [11] , the same authors recovered 200 sequential A. fumigatus from 26 immunocompromised patients with invasive aspergillosis or bronchial colonization and tested them for their in vitro susceptibility to posaconazole, itraconazole, voriconazole, terbinafine and amphotericin B. Antifungal susceptibilities of the isolates recovered before treatment were not significantly different from those of isolates recovered after the onset of antifungal therapy, suggesting that the emergence of resistance in A. fumigatus during antifungal therapy with amphotericin B or itraconazole is an uncommon phenomenon.
Two studies made interesting observations about the use of combined therapy. Kontoyiannis et al . [12] showed that previous exposure of A. fumigatus to itraconazole resulted in dose-dependent enhanced effects of caspofungin and vice versa. Liu et al . [13] suggested that pre-exposure of A. fumigatus to fluconazole attenuates the in vitro fungicidal activity of subsequent itraconazole against it. These data substantiate a clinical observation that prior fluconazole use has been associated with an increasing incidence of invasive aspergillosis in leukemia patients [13] .
The ergosterol biosynthesis pathway in A. fumigatus
The genes involved in the ergosterol biosynthesis (ERG ) in Aspergillus spp. and other fungal species are shown in Table 1 . About 20 genes are involved in the ergosterol biosynthesis pathway. Basic knowledge of the aspergilli ERG pathway is of great importance because it can be used in the development of inhibitors with increased activity or a broader spectrum. Comparative analysis of this pathway in three Aspergillus spp. showed that there are several duplicated genes in this pathway. Interestingly, erg3 showed two, three, and four copies in Aspergillus nidulans, A. fumigatus and A. oryzae, respectively, while erg11 presented two copies in A. nidulans and A. fumigatus, and three copies in A. oryzae. Besides that, several other genes in the pathway have more than one copy, such as erg4 and erg10. Other mould species, such as Fusarium graminearum , showed two erg3 genes, and three and two erg11 genes in Magnaporthe grisea and F. graminearum , respectively. Very little is known about the genetics and biochemistry of the ergosterol biosynthesis pathway in Aspergillus spp. However, Mellado et al . [14] have shown that both copies of the A. fumigatus ERG11 are expressed and that other aspergilli, such as A. terreus and A . flavus, also have two different but closely related ERG11 genes. In several yeasts, such as Candida albicans and Saccharomyces cerevisiae, the ERG genes are single-copy. Fig. 1 shows phylogenetic trees for the erg3 and erg11 genes from Aspergillus spp. and the other species shown in Table 1 . There is a sequence conservation of the corresponding erg3 and erg11 genes among the different Aspergillus spp. For example, the erg3A and erg3B are clustered in two different branches while the A. oryzae erg3C clusters together with erg3B (Fig. 1A) . The same behavior is observed for the Aspergillus erg11 genes (Fig. 1B) . These results suggest that although these genes evolved from common ancestors, the different erg3 and erg11 genes display differences in their sequence that could be related to the evolution of their biological function. The existence of several duplicated genes in the ERG pathway could be the basis of a good strategy to modulate the composition and fluidity of the cell membrane. This could confer several adaptative advantages to colonize new environments and also, to counteract antifungal drugs.
The azoles block the ergosterol biosynthesis pathway by inhibiting the enzyme 14-a-demethylase, product of the CYP51/erg11 [15] . Fungal azole resistance involves both amino acid changes in the target site that alter drug-target interactions and those that decrease net azole accumulation [16 Á/18] . Compensatory pathways have been documented for the mechanisms of resistance to the azole and polyene classes and involve alterations of specific steps in ergosterol biosynthesis [19, 20] . For example, analysis of the sterol compositions of two separate azole-resistant C. albicans clinical isolates revealed the accumulation of Fig. 1 Unrooted phylogenetic tree of ERG3 and ERG11 genes in fungal species. Predicted Erg3 (a) and Erg11 (b) proteins from six fungal species are aligned and a neighbor-join tree was constructed using CLUSTAL_X [29] . ergosta-7,22-dienol, which is a feature consistent with the absence of sterol D 5,6 -desaturase activity, which is encoded by erg3 [20 Á/23]. Table 2 shows the mutations observed in the A. fumigatus CYP51A gene that confer azole-resistance. The resistance conferred by some of these mutations in the CYP51A gene was validated by introducing the mutated versions of this gene into a recipient wild type strain. Recently Xiao et al. [24] , combining docking calculations with information gained from these substitutions that resulted in azole resistance, proposed a basis for why particular CYP51A mutations have more profound effects on the binding of some azoles than others. These authors suggested that the long side chains of posoconazole and itraconazole occupy a specific channel within CYP51A and that this additional interaction, which is not available to voriconazole and fluconazole, serves to stabilize the binding of these azoles to the mutated CYP51A proteins.
Another aspect of azole resistance conferred by CYP51 genes is that they can confer resistance when overexpressed. Osherov et al . [25] showed that overexpression of the A. nidulans CYP51A/pdmA/erg11 gene into A. fumigatus resulted in increased resistance to itraconazole. These results indicate that triazole resistance in clinical isolates of moulds may result from amplification or overexpression of the P-450 14a-demethylase.
Transporter-encoding genes in A. fumigatus
Reduced intracellular accumulation has also been correlated with overexpression of multidrug resistance (MDR) efflux transporter genes of the ATP-binding cassette (ABC) and the major facilitator superfamily (MFS) classes [19] . Table 3 shows the number of MFS and ABC transporters from Aspergillus spp. when compared to other fungal species. In general, Aspergillus spp. have proportionally more MFS transporter encoding genes than S. cerevisiae, S. pombe, and Neurospora crassa . The drug:H ' (12 and 14 spanners) sub-families are proportionally greater than in the other species. Although the numbers of ABC transporter encoding genes are comparable, again the Aspergillus spp. have more ABC transporters related to multidrug permease than the other species. These increased numbers could represent the presence of several and diverse toxic compounds in the very heterogeneous environments in which these fungi grow. This environmental scenario could have assisted the selection of new variants of transporters by gene duplication. In contrast to the extensive number of 
Conclusions
For the clinician, the main issue of concern about antifungal resistance are: how commonly does it occur and how often does it in failure of treatment. Impaired host defences and delayed diagnosis are considered the primary reasons for a poor outcome in invasive aspergillosis; resistance to antifungal drugs has not been a major concern [30] . Of 900 isolates of A. fumigatus tested against itraconazole, 2.1% are reported to be resistant in vitro [31] . Moreover, drug resistance in filamentous fungi has been a technically challenging area to study, and there have been no standardized in vitro susceptibility methods [30] . Of course, NCCLS has published a standardized method for in vitro testing of filamentous fungi, based on susceptibility tests for yeasts [32] . However, it is necessary more work to refine a tool to measure in vitro activity of drugs aiming to study the phenomenon of resistance in filamentous fungi. Accordingly, based on the development of such a tool, it would be possible to have precise information about drug resistance in A. fumigatus. As in other species, such as Candida spp. (for a review, see [17] ), there is some evidence to show that resistance in A. fumigatus azole-resistant mutants has evolved by mutations in the target gene, the cyp51A / erg11. However, there is no evidence about the participation of the erg3 gene in azole resistance in A. fumigatus. The A. fumigatus ergosterol biosynthesis pathway is very complex and there are several questions that need to be addressed, such as whether CYP51B gene is also participating in the process of azole resistance and what will happen with the ergosterol content in the cell membrane if the erg3 genes were mutated. Additionally, although there is some indirect evidence regarding the transcriptional induction of few transporter encoding genes in azole-resistant mutants Á/ and also in the wild type when induced with itraconazole Á/ there is no report showing direct evidence of the involvement of a transporter gene in azole resistance.
The recent sequencing of the genome of A. fumigatus coupled to the development of genetical tools for gene manipulation and microarray analysis might facilitate research on azole-resistance in this important fungal pathogen.
